Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy

Rie Amamoto, Mikako Yagi, Yoo Hyun Song, Yoshinao Oda, Masazumi Tsuneyoshi, Seiji Naito, Akira Yokomizo, Kentaro Kuroiwa, Shoji Tokunaga, Seiji Kato, Hisahide Hiura, Tomohiro Samori, Dongchon Kang, Takeshi Uchiumi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Mitochondria are key organelles for ATP production and apoptosis. Therefore, impairment of mitochondria can modulate or accelerate cancer progression. p32, originally identified as a pre-mRNA splicing factor SF2/ASF-associated protein, is localized predominantly in the mitochondrial matrix and involved in mitochondria respiration. Recently, p32 was implicated in apoptosis and resultantly cancer progression. However, little is known about the expression and function of p32 in human tumors including prostate cancer. Here, we investigated the expression of p32 in 148 prostate carcinoma tissues by immunohistochemistry and found a positive correlation of p32 expression to clinicopathological parameters including follow-up data. p32 is highly expressed in prostate tumor samples and its expression is significantly associated with the Gleason score, pathological stage and relapse. For localized cancers, high p32 is a strong and independent predictor of clinical recurrence in multivariate analysis (P=0.01). In addition, p32 is overexpressed in the prostate cancer cell lines examined. The selective knockdown of p32 by RNA interference inhibits the growth of prostate cancer cell lines but not of a non-cancerous cell line. The p32 RNA interference decreases cyclin D1, increases p21 expression and causes a G1/S cell cycle arrest in prostate cancer cells. These data suggest that p32 is critical for prostate cancer cell proliferation and may be a novel marker of clinical progression in prostate cancer.

Original languageEnglish
Pages (from-to)639-647
Number of pages9
JournalCancer Science
Volume102
Issue number3
DOIs
Publication statusPublished - Mar 1 2011

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Recurrence
Mitochondria
Neoplasms
RNA Interference
Cell Line
Prostate
Apoptosis
G1 Phase Cell Cycle Checkpoints
Neoplasm Grading
Cyclin D1
RNA Precursors
Organelles
Respiration
Multivariate Analysis
Adenosine Triphosphate
Biomarkers
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy. / Amamoto, Rie; Yagi, Mikako; Song, Yoo Hyun; Oda, Yoshinao; Tsuneyoshi, Masazumi; Naito, Seiji; Yokomizo, Akira; Kuroiwa, Kentaro; Tokunaga, Shoji; Kato, Seiji; Hiura, Hisahide; Samori, Tomohiro; Kang, Dongchon; Uchiumi, Takeshi.

In: Cancer Science, Vol. 102, No. 3, 01.03.2011, p. 639-647.

Research output: Contribution to journalArticle

Amamoto, Rie ; Yagi, Mikako ; Song, Yoo Hyun ; Oda, Yoshinao ; Tsuneyoshi, Masazumi ; Naito, Seiji ; Yokomizo, Akira ; Kuroiwa, Kentaro ; Tokunaga, Shoji ; Kato, Seiji ; Hiura, Hisahide ; Samori, Tomohiro ; Kang, Dongchon ; Uchiumi, Takeshi. / Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy. In: Cancer Science. 2011 ; Vol. 102, No. 3. pp. 639-647.
@article{63ebab2a6b0843a595e0ee70f039843b,
title = "Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy",
abstract = "Mitochondria are key organelles for ATP production and apoptosis. Therefore, impairment of mitochondria can modulate or accelerate cancer progression. p32, originally identified as a pre-mRNA splicing factor SF2/ASF-associated protein, is localized predominantly in the mitochondrial matrix and involved in mitochondria respiration. Recently, p32 was implicated in apoptosis and resultantly cancer progression. However, little is known about the expression and function of p32 in human tumors including prostate cancer. Here, we investigated the expression of p32 in 148 prostate carcinoma tissues by immunohistochemistry and found a positive correlation of p32 expression to clinicopathological parameters including follow-up data. p32 is highly expressed in prostate tumor samples and its expression is significantly associated with the Gleason score, pathological stage and relapse. For localized cancers, high p32 is a strong and independent predictor of clinical recurrence in multivariate analysis (P=0.01). In addition, p32 is overexpressed in the prostate cancer cell lines examined. The selective knockdown of p32 by RNA interference inhibits the growth of prostate cancer cell lines but not of a non-cancerous cell line. The p32 RNA interference decreases cyclin D1, increases p21 expression and causes a G1/S cell cycle arrest in prostate cancer cells. These data suggest that p32 is critical for prostate cancer cell proliferation and may be a novel marker of clinical progression in prostate cancer.",
author = "Rie Amamoto and Mikako Yagi and Song, {Yoo Hyun} and Yoshinao Oda and Masazumi Tsuneyoshi and Seiji Naito and Akira Yokomizo and Kentaro Kuroiwa and Shoji Tokunaga and Seiji Kato and Hisahide Hiura and Tomohiro Samori and Dongchon Kang and Takeshi Uchiumi",
year = "2011",
month = "3",
day = "1",
doi = "10.1111/j.1349-7006.2010.01828.x",
language = "English",
volume = "102",
pages = "639--647",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy

AU - Amamoto, Rie

AU - Yagi, Mikako

AU - Song, Yoo Hyun

AU - Oda, Yoshinao

AU - Tsuneyoshi, Masazumi

AU - Naito, Seiji

AU - Yokomizo, Akira

AU - Kuroiwa, Kentaro

AU - Tokunaga, Shoji

AU - Kato, Seiji

AU - Hiura, Hisahide

AU - Samori, Tomohiro

AU - Kang, Dongchon

AU - Uchiumi, Takeshi

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Mitochondria are key organelles for ATP production and apoptosis. Therefore, impairment of mitochondria can modulate or accelerate cancer progression. p32, originally identified as a pre-mRNA splicing factor SF2/ASF-associated protein, is localized predominantly in the mitochondrial matrix and involved in mitochondria respiration. Recently, p32 was implicated in apoptosis and resultantly cancer progression. However, little is known about the expression and function of p32 in human tumors including prostate cancer. Here, we investigated the expression of p32 in 148 prostate carcinoma tissues by immunohistochemistry and found a positive correlation of p32 expression to clinicopathological parameters including follow-up data. p32 is highly expressed in prostate tumor samples and its expression is significantly associated with the Gleason score, pathological stage and relapse. For localized cancers, high p32 is a strong and independent predictor of clinical recurrence in multivariate analysis (P=0.01). In addition, p32 is overexpressed in the prostate cancer cell lines examined. The selective knockdown of p32 by RNA interference inhibits the growth of prostate cancer cell lines but not of a non-cancerous cell line. The p32 RNA interference decreases cyclin D1, increases p21 expression and causes a G1/S cell cycle arrest in prostate cancer cells. These data suggest that p32 is critical for prostate cancer cell proliferation and may be a novel marker of clinical progression in prostate cancer.

AB - Mitochondria are key organelles for ATP production and apoptosis. Therefore, impairment of mitochondria can modulate or accelerate cancer progression. p32, originally identified as a pre-mRNA splicing factor SF2/ASF-associated protein, is localized predominantly in the mitochondrial matrix and involved in mitochondria respiration. Recently, p32 was implicated in apoptosis and resultantly cancer progression. However, little is known about the expression and function of p32 in human tumors including prostate cancer. Here, we investigated the expression of p32 in 148 prostate carcinoma tissues by immunohistochemistry and found a positive correlation of p32 expression to clinicopathological parameters including follow-up data. p32 is highly expressed in prostate tumor samples and its expression is significantly associated with the Gleason score, pathological stage and relapse. For localized cancers, high p32 is a strong and independent predictor of clinical recurrence in multivariate analysis (P=0.01). In addition, p32 is overexpressed in the prostate cancer cell lines examined. The selective knockdown of p32 by RNA interference inhibits the growth of prostate cancer cell lines but not of a non-cancerous cell line. The p32 RNA interference decreases cyclin D1, increases p21 expression and causes a G1/S cell cycle arrest in prostate cancer cells. These data suggest that p32 is critical for prostate cancer cell proliferation and may be a novel marker of clinical progression in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=79951725426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951725426&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2010.01828.x

DO - 10.1111/j.1349-7006.2010.01828.x

M3 - Article

VL - 102

SP - 639

EP - 647

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 3

ER -